Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.

Antiviral research - 1 Aug 2022

Muller Clotilde, Tilloy Valentin, Frobert Emilie, Feghoul Linda, Garrigue Isabelle, Lepiller Quentin, Mirand Audrey, Sidorov Egor, Hantz Sébastien, Alain Sophie

Abstract excerpt

BACKGROUND: Letermovir (LMV) is a human cytomegalovirus (HCMV) terminase inhibitor indicated as prophylaxis for HCMV-positive stem-cell recipients. Its mechanism of action involves at least the viral terminase proteins pUL56, pUL89 and pUL51. Despite its efficiency, resistance mutations were characterized in vitro and in vivo, largely focused on pUL56. To date, mutations in pUL51 in clinical resistance remain to...

Topics

Acetates
Antiviral Agents
Cytomegalovirus
Drug Resistance, Viral
Endodeoxyribonucleases
Humans
Mutation
Quinazolines
Viral Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35690130
DOI: 10.1016/j.antiviral.2022.105361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.PMID 35690130Read ↗

A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.Semantic proximity Read ↗

Deciphering letermovir's mode of action and resistance mutation effects.Semantic proximity Read ↗

Identification of a binding pocket of letermovir in the terminase subunit pUL56 of human cytomegalovirusSemantic proximity Read ↗

Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.Semantic proximity Read ↗

Competitive Fitness of Cytomegalovirus Mutants Bearing Changes in the UL56 Terminase Subunit, Associated with Letermovir-Resistance, in Presence and Absence of Antivirals.Semantic proximity Read ↗

The C-terminal part of the human cytomegalovirus terminase subunit pUL51 is central for terminase complex assembly.Semantic proximity Read ↗

New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir.Semantic proximity Read ↗

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Semantic proximity Read ↗

De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene productsSemantic proximity Read ↗

Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.